From: Insights into prescribing patterns for antidepressants: an evidence-based analysis
Factors | Log Odds | Factors | Log Odds | Factors | Log Odds |
---|---|---|---|---|---|
amitriptyline | bupropion | citalopram | |||
Hx of amitriptyline HCL | 2.61 | Hx of bupropion HCL | 1.97 | Hx of citalopram hydrobromide | 2.19 |
4 + previous antidepressants | 0.67 | 4 + previous antidepressants | 0.36 | 4 + previous antidepressants | 0.97 |
Headache | 0.37 | Tobacco use disorder | 0.32 | loratadine | 0.25 |
Unspecified migraine | 0.3 | Abnormal weight gain | 0.27 | 2 or 3 previous antidepressants | 0.16 |
Herpes zoster | 0.26 | Different last antidepressant and no remission | 0.23 | lovastatin or hydrocodone/homatropine | 0.14 |
desvenlafaxine | doxepin | duloxetine | |||
Hx of desvenlafaxine succinate | 3.67 | Hx of doxepin HCL | 3.71 | Hx of duloxetine HCL | 2.32 |
fenofibrate nanocrystallized | 0.36 | Unspecified Urticaria | 0.9 | Unspecified myalgia and myositis | 0.27 |
lisdexamfetamine dimesylate | 0.36 | hydroxyzine HCL | 0.55 | guaifenesin/p-ephed HCL | 0.26 |
olmesartan medoxomil | 0.36 | Opioid type dependence | 0.54 | pregabalin | 0.22 |
levocetirizine dihydrochloride | 0.35 | Other atopic dermatitis | 0.53 | gabapentin | 0.22 |
escitalopram | fluoxetine | mirtazapine | |||
Hx of escitalopram oxalate | 1.83 | Hx of fluoxetine HCL | 2.55 | Hx of mirtazapine | 2.4 |
4 + previous antidepressants | 0.99 | 4 + previous antidepressants | 0.9 | Age 80–89 | 1.43 |
Other miscellaneous procedures | 0.37 | Premenstrual tension syndromes | 0.75 | Age 65–79 | 0.84 |
2 or 3 previous antidepressants | 0.19 | Age 13–19 | 0.5 | Loss of weight | 0.62 |
guaifenesin/phenylephrine HCL | 0.19 | 2 or 3 previous antidepressants | 0.21 | Anorexia | 0.37 |
nortriptyline | paroxetine | sertraline | |||
Hx of nortriptyline HCL | 3.33 | Hx of paroxetine HCL, | 2.94 | Hx of sertraline HCL | 2.11 |
Headache | 0.56 | 4 + previous antidepressants, | 1.11 | 4 + previous antidepressants | 1.2 |
Unspecified migraine | 0.38 | loratadine | 0.32 | Supervision of other normal pregnancy | 0.69 |
Unspecified tinnitus | 0.35 | Gynecologic examination | 0.3 | Age 13–19 | 0.38 |
Unspecified hereditary and idiopathic peripheral neuropathy | 0.32 | 2 or 3 previous antidepressants | 0.26 | Incidental pregnant state | 0.36 |
trazodone | venlafaxine | Â | |||
Hx of trazodone HCL | 2.05 | Hx of venlafaxine HCL | 2.59 | Â | Â |
Unspecified insomnia | 0.47 | Breast cancer | 0.58 | Â | Â |
Age 80–89 | 0.41 | Gynecologic examination | 0.21 |  |  |
Persistent disorder of initiating or maintaining sleep | 0.32 | Other miscellaneous procedures | 0.21 | Â | Â |
lithium carbonate | 0.31 | Symptomatic menopausal or female climacteric states | 0.18 | Â | Â |